GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman LlcMereo BioPharma Faces Class Action Over Failed Clinical Trials, Alleged Investor Deception
Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC. Investors from June 2023-December 2025 eligible; lead plaintiff deadline April 2026.
MREOsecurities fraudclass action lawsuit